Literature DB >> 16010558

Pulmonary arterial hypertension in mixed connective tissue disease: successful treatment with Iloprost.

Judit Végh1, Györgyike Soós, István Csipõ, Nóra Demeter, Thomas Ben, Balázs Dezsõ, Margit Zeher, Katalin Dévényi, János Gaál, Gyula Szegedi, Edit Bodolay.   

Abstract

This paper describes a 61-year-old woman who presented with mixed connective tissue disease, which was complicated by the development of pulmonary arterial hypertension (PAH). Her condition worsened rapidly, with development of haemopthysis, tachypnoe and cardiac arrest. Doppler echocardiography showed a high systolic pulmonary arterial pressure (98 mmHg), confirmed by the right heart catheterization. Vasculopathy of the pulmonary artery vessels was detected following open lung biopsy. No pulmonary embolism was found. Because of suspicion of flare of her underlying disease, which leads to PAH, immunosuppressive treatment was started with high doses of corticosteroid and cyclophosphamide, in combination with the prostacyclin analogue, Iloprost, and low molecular weight heparin. The therapy resulted in slow recovery over 6 weeks, with control echocardiography showing normalization of the high pulmonary pressure, and the patient being capable of returning to everyday activities.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16010558     DOI: 10.1007/s00296-005-0616-8

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  33 in total

Review 1.  Mixed connective tissue disease.

Authors:  R W Hoffman; E L Greidinger
Journal:  Curr Opin Rheumatol       Date:  2000-09       Impact factor: 5.006

2.  Novel mode of action of iloprost: in vitro down-regulation of endothelial cell adhesion molecules.

Authors:  S Della Bella; M Molteni; C Mocellin; S Fumagalli; P Bonara; R Scorza
Journal:  Prostaglandins Other Lipid Mediat       Date:  2001-06       Impact factor: 3.072

3.  Two fatal cases of mixed connective tissue disease. Description of case histories terminating as progressive systemic sclerosis.

Authors:  R Manthorpe; H Elling; J T van der Meulen; S F Sørensen
Journal:  Scand J Rheumatol       Date:  1980       Impact factor: 3.641

4.  The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.

Authors:  S Rich; E Kaufmann; P S Levy
Journal:  N Engl J Med       Date:  1992-07-09       Impact factor: 91.245

5.  Anticardiolipin antibodies are associated with pulmonary hypertension in patients with mixed connective tissue disease or systemic lupus erythematosus.

Authors:  M Miyata; K Suzuki; F Sakuma; H Watanabe; S Kaise; T Nishimaki; R Kasukawa
Journal:  Int Arch Allergy Immunol       Date:  1993       Impact factor: 2.749

6.  Age and risk of pulmonary arterial hypertension in scleroderma.

Authors:  Lionel Schachna; Fredrick M Wigley; Betty Chang; Barbara White; Robert A Wise; Allan C Gelber
Journal:  Chest       Date:  2003-12       Impact factor: 9.410

7.  Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years.

Authors:  L Bettoni; A Geri; P Airò; E Danieli; I Cavazzana; C Antonioli; L Chiesa; F Franceschini; A Grottolo; A Zambruni; E Radaeli; R Cattaneo
Journal:  Clin Rheumatol       Date:  2002-06       Impact factor: 2.980

Review 8.  Respiratory complications in mixed connective tissue disease.

Authors:  U B Prakash
Journal:  Clin Chest Med       Date:  1998-12       Impact factor: 2.878

9.  Increased serum angiotensin I-converting enzyme activity in patients with mixed connective tissue disease and pulmonary hypertension.

Authors:  T Ozawa; Y Ninomiya; T Honma; M Kikuchi; T Sato; M Nakano; M Arakawa
Journal:  Scand J Rheumatol       Date:  1995       Impact factor: 3.641

View more
  3 in total

1.  The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin.

Authors:  Zo Rakotoniaina; Pascal Guerard; Frederic Lirussi; Françoise Goirand; Luc Rochette; Monique Dumas; Marc Bardou
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-11-11       Impact factor: 3.000

2.  Celecoxib but not the combination of celecoxib+atorvastatin prevents the development of monocrotaline-induced pulmonary hypertension in the rat.

Authors:  Zo Rakotoniaina; Pascal Guerard; Frédéric Lirussi; Luc Rochette; Monique Dumas; Françoise Goirand; Marc Bardou
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-06-10       Impact factor: 3.000

3.  Treatment of Vasodilator-resistant Mixed Connective Tissue Disease-associated Pulmonary Arterial Hypertension with Glucocorticoid and Cyclophosphamide.

Authors:  Eri Sugawara; Masaru Kato; Ryo Hisada; Kenji Oku; Toshiyuki Bohgaki; Tetsuya Horita; Shinsuke Yasuda; Tatsuya Atsumi
Journal:  Intern Med       Date:  2017-02-15       Impact factor: 1.271

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.